Proteolysis-targeting chimeras in drug development: A safety perspective

被引：149

作者：

Moreau, Kevin ^{[1
]}

Coen, Muireann ^{[1
,6
]}

Zhang, Andrew X. ^{[2
]}

Pachl, Fiona ^{[2
]}

Castaldi, M. Paola ^{[2
]}

Dahl, Goran ^{[3
]}

Boyd, Helen ^{[4
]}

Scott, Clay ^{[5
]}

Newham, Pete ^{[1
]}

机构：

[1] AstraZeneca, Oncol Safety, Clin Pharmacol & Safety Sci R&D, Sci Pk, Cambridge, England

[2] AstraZeneca, Discovery Sci, BioPharmaceut R&D, Boston, MA USA

[3] AstraZeneca, Struct Biophys & Fragment Based Lead Generat, Discovery Sci, R&D, Gothenburg, Sweden

[4] AstraZeneca, Business Planning & Operat, Clin Pharmacol & Safety Sci, R&D, Cambridge, England

[5] AstraZeneca, Oncol Safety, Clin Pharmacol & Safety Sci R&D, Boston, MA USA

[6] Imperial Coll, Biomol Med, Med Syst, Dept Metab Digest & Reprod, London SW7 2AZ, England

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2020年 / 177卷 / 08期

关键词：

PROTEIN-DEGRADATION; CONCISE GUIDE; SELECTIVE DEGRADATION; KNOCKDOWN; INDISULAM; PROTACS; DESIGN; LIGASE; MODEL; GSPT1;

D O I：

10.1111/bph.15014

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Proteolysis-targeting chimeras are a new drug modality that exploits the endogenous ubiquitin proteasome system to degrade a protein of interest for therapeutic benefit. As the first-generation of proteolysis-targeting chimeras have now entered clinical trials for oncology indications, it is timely to consider the theoretical safety risks inherent with this modality which include off-target degradation, intracellular accumulation of natural substrates for the E3 ligases used in the ubiquitin proteasome system, proteasome saturation by ubiquitinated proteins, and liabilities associated with the "hook effect" of proteolysis-targeting chimeras This review describes in vitro and non-clinical in vivo data that provide mechanistic insight of these safety risks and approaches being used to mitigate these risks in the next generation of proteolysis-targeting chimera molecules to extend therapeutic applications beyond life-threatening diseases.

引用

页码：1709 / 1718

页数：10

共 60 条

[1] THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors [J].

Alexander, Stephen P. H. ;

Fabbro, Doriano ;

Kelly, Eamonn ;

Mathie, Alistair ;

Peters, John A. ;

Veale, Emma L. ;

Armstrong, Jane F. ;

Faccenda, Elena ;

Harding, Simon D. ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. .

BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 :S247-S296

[2]

Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS297, DOI [10.1111/bph.14752, 10.1111/bph.14749]

[3] THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors [J].

Alexander, Stephen P. H. ;

Cidlowski, John A. ;

Kelly, Eamonn ;

Mathie, Alistair ;

Peters, John A. ;

Veale, Emma L. ;

Armstrong, Jane F. ;

Faccenda, Elena ;

Harding, Simon D. ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. .

BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 :S229-S246

[4] THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets [J].

Alexander, Stephen P. H. ;

Kelly, Eamonn ;

Mathie, Alistair ;

Peters, John A. ;

Veale, Emma L. ;

Armstrong, Jane F. ;

Faccenda, Elena ;

Harding, Simon D. ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Buneman, O. Peter ;

Cidlowski, John A. ;

Christopoulos, Arthur ;

Davenport, Anthony P. ;

Fabbro, Doriano ;

Spedding, Michael ;

Striessnig, Joerg ;

Davies, Jamie A. .

BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 :S1-S20

[5] p63 is a cereblon substrate involved in thalidomide teratogenicity [J].

Asatsuma-Okumura, Tomoko ;

Ando, Hideki ;

De Simone, Marco ;

Yamamoto, Junichi ;

Sato, Tomomi ;

Shimizu, Nobuyuki ;

Asakawa, Kazuhide ;

Yamaguchi, Yuki ;

Ito, Takumi ;

Guerrini, Luisa ;

Handa, Hiroshi .

NATURE CHEMICAL BIOLOGY, 2019, 15 (11) :1077-+

[6] Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer [J].

Bai, Longchuan ;

Zhou, Bing ;

Yang, Chao-Yie ;

Ji, Jiao ;

McEachern, Donna ;

Przybranowski, Sally ;

Jiang, Hui ;

Hu, Jiantao ;

Xu, Fuming ;

Zhao, Yujun ;

Liu, Liu ;

Fernandez-Salas, Ester ;

Xu, Jing ;

Dou, Yali ;

Wen, Bo ;

Sun, Duxin ;

Meagher, Jennifer ;

Stuckey, Jeanne ;

Hayes, Daniel F. ;

Li, Shunqiang ;

Ellis, Matthew J. ;

Wang, Shaomeng .

CANCER RESEARCH, 2017, 77 (09) :2476-2487

[7] Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead [J].

Bondeson, Daniel P. ;

Smith, Blake E. ;

Burslem, George M. ;

Buhimschi, Alexandru D. ;

Hines, John ;

Jaime-Figueroa, Saul ;

Wang, Jing ;

Hamman, Brian D. ;

Ishchenko, Alexey ;

Crews, Craig M. .

CELL CHEMICAL BIOLOGY, 2018, 25 (01) :78-+

[8]

Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]

[9] Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML [J].

Brand, Matthias ;

Jiang, Baishan ;

Bauer, Sophie ;

Donovan, Katherine A. ;

Liang, Yanke ;

Wang, Eric S. ;

Nowak, Radoslaw P. ;

Yuan, Jingting C. ;

Zhang, Tinghu ;

Kwiatkowski, Nicholas ;

Muller, Andre C. ;

Fischer, Eric S. ;

Gray, Nathanael S. ;

Winter, Georg E. .

CELL CHEMICAL BIOLOGY, 2019, 26 (02) :300-+

[10] Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex [J].

Bussiere, Dirksen E. ;

Xie, Lili ;

Srinivas, Honnappa ;

Shu, Wei ;

Burke, Ashley ;

Be, Celine ;

Zhao, Junping ;

Godbole, Adarsh ;

King, Dan ;

Karki, Rajeshri G. ;

Hornak, Viktor ;

Xu, Fangmin ;

Cobb, Jennifer ;

Carte, Nathalie ;

Frank, Andreas O. ;

Frommlet, Alexandra ;

Graff, Patrick ;

Knapp, Mark ;

Fazal, Aleem ;

Okram, Barun ;

Jiang, Songchun ;

Michellys, Pierre-Yves ;

Beckwith, Rohan ;

Voshol, Hans ;

Wiesmann, Christian ;

Solomon, Jonathan M. ;

Paulk, Joshiawa .

NATURE CHEMICAL BIOLOGY, 2020, 16 (01) :15-+

← 1 2 3 4 5 6 →